Serono SA (SRA)
Loading...
Symbols:
SRA Forum Topics
loading ...Recent SRA Articles
- Vanguard Health Care Fund's Edward Owens: Buys, Sells, Portfolio
- Biotech Stocks Day In Review: Alfacell Receives Orphan Drug Status For Onconase
- Biotech Stocks Day-In-Review: Renovis Cuts Staff By 40%
- Biotech Stocks Day-in-Review: BioCryst Begins Pivotal Trial of Fodosine
- Teva Volatility Goes With The Territory
- Despite Cramer's Recommendation, Infertility Isn't Bull Market (SRA, INMD)
- Fate of Serono: J&J Hires Citigroup to Examine a Formal Bid (SRA, JNJ, GDT, STJ, ELN, BIIB)
-
Teva's MS Drug Copaxone: A Turnaround Winner? (BIIB, ELN, SRA, TEVA)
on Nov 16, 2005| by
- The Future of Tysabri: A Reader’s Perspective (ELN, BIIB, SRA)
- Serono Settles Serostim U.S. Government Investigation (SRA)
- Full List of Articles »
Trading Center
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »
Editors
General Discussion on SRA
Is this a buy or a sell? ReplyEditors
Teva Volatility Goes With The Territory [view article]
Franz, thanks for the correction. Article updated to the proper name. ReplyTraussnig
Teva Volatility Goes With The Territory [view article]
Good morning Shlomo.Please make sure to change the name and the symbol link for Merck. The company buying Serono is the Merck KGaA, based in Darmstadt. The symbol is the same (MRK)but the excgange identifier is different.
MRK GR equity on Bloomberg.
Best regards Reply
The Future of Tysabri: A Reader’s Perspective (ELN, BIIB, SRA) [view article]
Boswells,One more thing. Thank you very much for your comment. Reply
The Future of Tysabri: A Reader’s Perspective (ELN, BIIB, SRA) [view article]
Your point is well taken. I would not be surprised if Tysabri comes back on the market, but only as a salvage treatment. However, I believe you are wrong when you say that, "What it all boils down to is how much of a personal risk one is willing to once all the other options you've tried...fail." If you are an MS patient and develop PML and die or are disabled, your loved one are more than likely to sue the doctor and the company; therefore, it is not simply the patients decision. Moreover, the FDA is concerned about the potential fallout of allowing a drug with potentially fatal side effects without defining the risks. At this point, there are a lot of questions that need to be answered: Does monontherapy increase risk or is it only combo therapy? If only combo, how long does a washout period need be before giving Tysabri? What will be the monitoring procedure? There is no effective diagnostic test. Rather than trying to make a prediction about Tysabri's fate, what I am really trying to say is that the risk/reward in playing this from an investment perspective is not there. ELN is trading as though Tysabri has a 100% probably of getting back on the market with blockbuster revenue potential. ReplyThe Future of Tysabri: A Reader’s Perspective (ELN, BIIB, SRA) [view article]
This is all well an fine that you can quote rates, market share and percentages of who has this and how much of what cocktail they may have taken. What it all boils down to is how much of a personal risk one is willing to take once all the other options you've tried for the last 6 years fail to keep the enemy at bay. I'm a firm believer, if you know all your options and make an informed decision, your future is in your hands. For some of us, Tysabri is the last stand, literally. Reply